Toxicity in combination immune checkpoint inhibitor and radiation therapy: A systematic review and meta-analysis-Reference-Cited by-同舟云学术

Toxicity in combination immune checkpoint inhibitor and radiation therapy: A systematic review and meta-analysis

Published:2020-10 Issue: Volume:151 Page:141-148
ISSN:0167-8140
Container-title:Radiotherapy and Oncology
language:en
Short-container-title:Radiotherapy and Oncology

Author:

Sha Congzhou M.,Lehrer Eric J.,Hwang Clara,Trifiletti Daniel M.,Mackley Heath B.,Drabick Joseph J.,Zaorsky Nicholas G.

Funder

American Cancer Society

Publisher

Elsevier BV

Subject

Radiology Nuclear Medicine and imaging,Oncology,Hematology

Reference78 articles.

1. Central Nervous System Cancers (Version 1.2019). Available from URL: https://www.nccn.org/professionals/physician_gls/pdf/cns.pdf [accessed March 27, 2019].

2. Toxicities of immunotherapy for the practitioner;Weber;J Clin Oncol,2015

3. Immune checkpoint blockade: a common denominator approach to cancer therapy;Topalian;Cancer Cell,2015

4. Melanoma brain metastases treated with stereotactic radiosurgery and concurrent pembrolizumab display marked regression; efficacy and safety of combined treatment;Anderson;J Immunother Cancer,2017

5. Concurrent immune checkpoint inhibitors and stereotactic radiosurgery for brain metastases in non-small cell lung cancer, melanoma, and renal cell carcinoma;Chen;Int J Radiat Oncol Biol Phys,2018

Cited by 70 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prospects of Synergy: Local Interventions and CAR T Cell Therapy in Solid Tumors;BioDrugs;2024-07-30

2. Pembrolizumab and low-dose, single-fraction radiotherapy for patients with relapsed or refractory multiple myeloma: a prospective, single-centre, single-group, open-label, phase 2 pilot trial in the USA;The Lancet Haematology;2024-07

3. Thrombocytopenia and hyperprogression after radiotherapy and camrelizumab treatment in an esophageal cancer patient with increased JAK2 gene copies: a case report;Frontiers in Oncology;2024-06-21

4. Oligo-residual disease in PD-1/PD-L1 inhibitor-treated metastatic non-small cell lung cancer: incidence, pattern of failure, and clinical value of local consolidative therapy;Cancer Immunology, Immunotherapy;2024-06-04

5. Amniotic extracelluar matrix microgels for attenuation of radiation-induced lung injury;Medical Hypotheses;2024-05